Nivolumab + ipilimumab (N+I) vs sunitinib (S) for treatment-naïve advanced or metastatic renal cell carcinoma (aRCC): Results from CheckMate 214, including overall survival by subgroups Meeting Abstract
| Authors: | Motzer, R. J.; Tannir, N. M.; McDermott, D. F.; Frontera, O. A.; Melichar, B.; Plimack, E. R.; Barthelemy, P.; George, S.; Neiman, V.; Porta, C.; Choueiri, T. K.; Powles, T.; Donskov, F.; Salman, P.; Kollmannsberger, C. K.; Rini, B.; Mekan, S.; McHenry, M. B.; Wind-Rotolo, M.; Hammers, H. J.; Escudier, B. |
| Abstract Title: | Nivolumab + ipilimumab (N+I) vs sunitinib (S) for treatment-naïve advanced or metastatic renal cell carcinoma (aRCC): Results from CheckMate 214, including overall survival by subgroups |
| Meeting Title: | 32nd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2017) |
| Journal Title: | Journal for ImmunoTherapy of Cancer |
| Volume: | 5 |
| Issue: | Suppl. 3 |
| Meeting Dates: | 2017 Nov 8-12 |
| Meeting Location: | National Harbor, MD |
| ISSN: | 2051-1426 |
| Publisher: | Biomed Central Ltd |
| Date Published: | 2017-12-07 |
| Start Page: | 89 |
| Language: | English |
| DOI: | 10.1186/s40425-017-0297-3 |
| PROVIDER: | manual |
| Notes: | Meeting Abstract: O38 -- Late-breaking abstract |
